Journal of cancer science and clinical therapeutics最新文献

{"title":"The Association of Programmed Death-Ligand 1 Expression with Clinicopathological Features, Lymph Node Metastasis and Survival Prognosis in Patients with Colorectal Carcinoma","authors":"Weifang Shao, Yanhua Xu, Suzhen Lin, Junshun Gao, Junli Gao, Hong Wang","doi":"10.26502/jcsct.5079163","DOIUrl":"https://doi.org/10.26502/jcsct.5079163","url":null,"abstract":"Colorectal carcinoma (CRC) is one of the most frequently encountered neoplasms with high morbidity and mortality. Activation of the programmed death protein 1/ programmed death ligand 1 (PD-1/PD-L1) pathway results in tumor immune evasion by suppressing the activity of T cells. The correlation of PD-L1 with clinicopathological features, lymph node metastasis and prognosis is less clear. The aim of present work was to study the relationship between PD-L1 and clinicopathological features and prognosis of CRC patients. Three hundred and eighty-six patients were included in this study. Serum PD-L1 was measured by ELISA, and PD-L1 on tumor cells was evaluated by immunohistochemistry. Pretreatment levels of PD-L1 were significantly elevated in CRC patient sera compared to healthy donors ( P <0.001). The mean value of PD-L1 in healthy donors, CRC with non-lymph node metastasis, and CRC with lymph node metastasis were 229.22±54.7pg/mL, 400.77±66.3pg/ mL, and 414.29±59.1pg/mL, respectively. The positive rate of PD-L1 in metastatic lymph node was higher than in primary tumor ( P <0.001). PD-L1 negative patients had higher five-year survival rate than PD-L1 positive patients (68.57% vs 46.98%, P =0.012). The univariate analysis indicated that tumor differentiation, lymph node metastasis, and PD-L1 were correlated with five-year survival rate of CRC patients (all P < 0.018). Multivariate analysis showed that lymph node metastasis and PD-L1 were independent prognostic factors (all P < 0.008). Our study demonstrates that PD-L1 negative patients have better five-year survival rate, and PD-L1 and lymph node metastasis are independent prognostic factors in CRC patients.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69347869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Percutaneous Nephrostomy for Uretric Obstruction due to Advanced Abdominopelvic Malignancy: A Retrospective Analysis","authors":"Rida Mansoor, M. Faisal, Shahan Raza, H. Ali, O. Shakeel, Zaeem Shahid, Haroon Hafiz","doi":"10.26502/jcsct.5079157","DOIUrl":"https://doi.org/10.26502/jcsct.5079157","url":null,"abstract":"The Role of Percutaneous Nephrostomy for Uretric Obstruction due to Advanced Abdominopelvic Malignancy: A Retrospective Analysis. Journal Cancer Science and Clinical Therapeutics 6 214-221. Abstract Introduction: In advanced or metastatic abdominopelvic malignancy, ureteric obstruction is a known complication. (PCN) is a diversion procedure for decompression in order to improve renal function. It is debatable whether PCN is an effective management to relieve ureteric obstruction in a stage IV abdominoperineal disease. The aim of the study is to determine the outcome of PCN tube insertion in a palliative care setting. Methodology: The study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore (SKMCH&RC). Data was retrieved from the electronic Hospital Information System (HIS) of the hospital. Duration of the study was from January, 2018 to December, 2020. We included patients who underwent percutaneous nephrostomy under palliative setting. Results: A total of 111 patients were included in the study. The median age at the time of nephrostomy was 4915.6 years. 67 patients (60.4%) were males, while 44 patients (39.6%) were females. Pre procedural median level of creatinine were was 3.3±3.36. Unilateral nephrostomy was performed in 71 patient (63.9%), while 40 patients (36.1%) underwent bilateral nephrostomy. Post-procedural mean creatinine level were 2.52 + 2.80. Relief of symptoms was observed among 68 patients (62.2%). 75 patients (67.6%) did not develop any complications after the procedure. The two most common complications of the procedure in our study were dislodgement (9%) and infection (9%). Conclusion: PCN is good for symptomatic and biochemical relief even in stage IV cancer, however due to increased incidence of complications in these patients the benefits might outweigh the risks.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insect Venoms and their Bioactive Components: A Novel Therapeutic Approach in Chronic Diseases and Cancer","authors":"Deepshikha Moran, U. Dutta, Ajaikumar B Kunnumakkara, Enush Daimari, B. Deka","doi":"10.26502/jcsct.5079176","DOIUrl":"https://doi.org/10.26502/jcsct.5079176","url":null,"abstract":"To counteract the growing burden of chronic diseases, discovery of highly selective target specific drugs is of utmost importance in present scenario. Various advanced therapeutic procedures and modern drugs have been developed and approved in last three decades for treating these disorders. The very first limitation of these therapies is their side effects, which are severe and long term. Also, these treatments are a costly affair and of limited therapeutic advantages. To overcome it, exploration and mining of natural products is much necessary. Phytotherapy is already well-established in the field of drug discovery. Focus should also be provided on zoo-therapy, as it is loaded with paramount of possibilities regarding disease treatment. Insect venoms are cocktail of bioactive components with different physiological actions that have undergone evolutionary refinement through a long time-scale. This evolutionary selection over time makes them more suitable candidate for target specific drug discovery. In this review we are trying to throw some light on some significant insect venom components with their mechanism of patho-physiological actions, relevance in the field of advanced drug discovery targeting chronic diseases including cancer.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obtaining a Recombinant Protein Based on the E7 Antigen of Human Papillomavirus Type 18","authors":"Rodriguez Rodriguez N,, Alfonso Chaviano AB,, Granadillo Rodríguez M,, Batte Figueredo A,, Torrens I","doi":"10.26502/jcsct.5079172","DOIUrl":"https://doi.org/10.26502/jcsct.5079172","url":null,"abstract":"Background: Cervical cancer is the fourth most common cancer in women worldwide and was the leading cause of death among approximately 300 000 cases in 2018. The main risk factor for developing this disease is the persistent infection of high-risk types of Human Papillomavirus (HPV); specifically, HPV-18 is recognized as one of the major contributors for adenocarcinoma and squamous cancer. There are three prophylactic vaccines to prevent infection by HPV, but these vaccines are not effective in infected people. On the other hand, despite the success of various types of therapeutic vaccine candidates in clinical trials, none of them is commercially available to treat women with HPV-related malignancies. As the methods used for obtaining those therapeutic candidates are awfully expensive, they could be inaccessible for developing countries. In this scenario, E7 antigen of HPV is considered an ideal target for developing therapeutic vaccines. In accordance with this, the aim of this work is to obtain a recombinant fusion protein with high levels of purity through a profitable process, which could be used as therapeutic alternative for treating tumors expressing the E7 antigen of HPV-18. Results: We have obtained the novel recombinant protein CIGB550-E718 that comprises the fusion between an E7 mutein of HPV-18 and the cell-penetrating peptide with immunostimulatory properties CIGB550. The expression of the fusion protein evaluated using two strains of E. coli and 16 culture media with different composition enabled us to choose the best setting in which the interest protein accounted for approximately 16% of the total cellular protein. The best results were obtained using BL21(DE3) cells as host system grown in a culture medium containing M9 salt, casein hydrolysate and glycerol as a carbon source. The recombinant protein was purified by a single affinity chromatographic step up to 90% purity. Yields of 32 mg of the CIGB550-E718 per liter of culture were achieved from 2.5 L scale. Conclusions: These results are a promising and cost-effective approach for the future production and scale-up of the protein CIGB550-E718, which could be a therapeutic alternative for treating women with lesions associated to HPV-18 infection.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model.","authors":"Laura C Gunder,&nbsp;Tyra H Moyer,&nbsp;Marissa R Ziolkowski,&nbsp;Margaret K Keating,&nbsp;Glen E Leverson,&nbsp;Wei Zhang,&nbsp;Evie H Carchman","doi":"10.26502/jcsct.5079153","DOIUrl":"https://doi.org/10.26502/jcsct.5079153","url":null,"abstract":"<p><strong>Introduction: </strong>Anal dysplasia is a growing health concern that over time can result in squamous cell carcinoma (SqCC) of the anus. In this study, we compare a topical versus systemic (oral) administration of LY3023414, a dual PI3K/mTOR inhibitor, to prevent anal carcinogenesis in a Human Papillomavirus (HPV) mouse model of anal cancer.</p><p><strong>Materials and methods: </strong><i>K14E6/E7</i> transgenic mice were used to model HPV-induced anal carcinogenesis. Mice with varying starting anal histologies (normal histology, low-grade, and high-grade anal dysplasia) were treated topically at the anus or systemically via oral gavage with LY3023414 with or without topical carcinogen for 20 weeks. Mice were monitored for overt anal tumor development and anal tissue was assessed for histology and markers of PI3K and mTOR activity (pAKT and pS6, respectively).</p><p><strong>Results: </strong>LY3023414 treatment, regardless of the mode of delivery, significantly decreased overt tumor development in mice starting with normal histology and low-grade anal dysplasia. Systemic LY3023414 treatment was more effective in delaying tumor onset than topical treatment. Mice treated with systemic LY3023414 had significantly reduced rates of anal SqCC when starting with normal and low-grade anal dysplasia compared to topical treatment. Topical treatment was only effective in reducing SqCC in the setting of low-grade dysplasia. LY3023414 inhibition of pAKT and pS6 expression varied with starting histology. Neither treatment mode was effective in the setting of high-grade anal dysplasia.</p><p><strong>Conclusion: </strong>Systemic LY3023414 treatment was more effective than topical application in delaying the progression of normal anal histology and low-grade dysplasia to anal cancer in HPV-associated mice.</p>","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"6 2","pages":"157-173"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10057096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Mechanism of Hepatitis B Virus X Gene in Promoting Hepatocellular Carcinoma","authors":"Xinyu Zhou, Donghong Liu, Zishuai Li, Jun Zhao, Shiliang Cai, Guangwen Cao","doi":"10.26502/jcsct.5079158","DOIUrl":"https://doi.org/10.26502/jcsct.5079158","url":null,"abstract":"The Mechanism of Hepatitis B Virus X Gene in Promoting Abstract Primary liver cancer (PLC) was the third leading cause of cancer death worldwide and hepatocellular carcinoma (HCC) accounts for 75-85% of PLC cases. Chronic hepatitis B virus (HBV) infection is the major cause of HCC globally. HBV carcinogenesis depends on three factors: viral replication, integration and evolution, and HBV X gene (HBx) plays a major role in these processes. HBx determines HBV replication and is also the main viral gene for integration and evolution. Recently, numerous new carcinogenic mechanisms of HBx, including epigenetic modification, stem-like signal pathway, metabolic regulation, immune suppression, and drug resistance, have being continuously explored. This article reviews the mechanism of HBx and its mutation in the occurrence and development of HCC, in order to provide a reference for a comprehensive understanding of HBV-HCC.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting the Role of Immunotherapy for Colorectal Cancer Treatment in Patients with Constitutional Mismatch Repair Deficiency","authors":"E. L. Eikenboom, E. Michiels, D. Grünhagen, M. de Vries, A. Wagner, M. Spaander","doi":"10.26502/jcsct.5079181","DOIUrl":"https://doi.org/10.26502/jcsct.5079181","url":null,"abstract":"","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Ketamine, S-Ketamine and MK 801 on Integrin Beta-3-mediated Cell Migration in Pancreatic Carcinoma.","authors":"Manuela Malsy,&nbsp;Veronika Hofer,&nbsp;Stephan Schmidbauer,&nbsp;Bernhard Graf,&nbsp;Anika Bundscherer","doi":"10.26502/jcsct.5079183","DOIUrl":"https://doi.org/10.26502/jcsct.5079183","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic ductal adenocarcinoma is one of the most aggressive malignancies in humans. The main reason for its unfavourable prognosis is the combination of rapid tumour growth, early-onset metastasis and currently still inadequate diagnostic and therapeutic options. Thus, only very few patients are eligible for radical resection of the primary tumour as the only curative treatment option available so far. In the perioperative period, tumour progression and metastasis are facilitated by the activation of key signalling pathways and the altered regulation of transcription factors. Various tumour entities have shown increased expression of the integrin-3 receptor subunit, which correlates with more rapid tumour progression and metastasis through advanced migration, invasion and proliferation. The influence of perioperative medication and postoperative pain management remains unclear. To investigate the effects of ketamine, s-ketamine and MK 801 on integrin beta-3-mediated cell migration in pancreatic cancer cells <i>in vitro</i>.</p><p><strong>Methods: </strong>The effects of ketamine, s-ketamine and MK 801 on integrin beta-3 expression were investigated with immunoblot. Cell migratory potentials were analysed using a Cell Migration Assay Kit with a Boyden chamber, in which cells migrate through a semipermeable membrane under different stimuli.</p><p><strong>Results: </strong>Stimulation with ketamine and MK 801 significantly promoted migration in pancreatic cancer cells, increasing the expression of integrin beta-3.</p><p><strong>Conclusion: </strong>Novel therapeutic approaches target the effective modulation of specific signalling and transcription pathways. The prerequisite for such 'target therapies' is comprehensive knowledge about the respective carcinogenesis. Further studies are required to identify the underlying disease mechanisms of pancreatic carcinoma.</p>","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"6 4","pages":"446-451"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10707593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>MET</i>-FISH Evaluation Algorithm: Proposal of a Simplified Method.","authors":"Roberta Castiglione,&nbsp;Christina Alidousty,&nbsp;Barbara Holz,&nbsp;Nicolai Duerbaum,&nbsp;Maike Wittersheim,&nbsp;Elke Binot,&nbsp;Sabine Merkelbach-Bruse,&nbsp;Nicolaus Friedrichs,&nbsp;Matthias S Dettmer,&nbsp;Alexander Bosse,&nbsp;Reinhard Buettner,&nbsp;Anne Maria Schultheis","doi":"10.26502/jcsct.5079180","DOIUrl":"https://doi.org/10.26502/jcsct.5079180","url":null,"abstract":"<p><p>MET amplifications (METamp) occur in 5% of NSCLC and represent in most case mechanisms of resistance to ALK and/or EGFR-targeted therapies. METamp detection can be performed using different techniques, although Fluorescence In-Situ Hybridization (FISH) remains the gold-standard, especially in the context of subclonality. To date current evaluation algorithms of MET amplifications are time consuming. Aim of the study was to identify a faster, equally reliable diagnostic algorithm for the detection of METamp, which is currently classified in negativity and low/intermediate/high-level amplification. N=497 NSCLC cases with available MET-FISH data had been selected. The results based on the first evaluated 20 cells had been re-calculated and compared with the definitive results based on 60 cells. For n=464 (93.4%) identical results had been obtained when counting 20 cells instead of 60 cells. Thirty-three cases (5.6%) showed a discrepancy, leading to an incorrect upgrade to a higher diagnostic category (n=25) and to an incorrect downgrade (n=8). We propose a simplified, yet equally reliable MET FISH-algorithm: after accurate screening of the whole tumor slide, twenty tumor cells have to be evaluated and results calculated: If the result is negative, or if all criteria of high-level METamp are fulfilled, the case can be signed out as such. All other cases should be considered as equivocal and additional 40 cells have to be counted. Given that, reliable results can be obtained by counting 20 cells only and an \"equivocal\" category for cases that need further investigation have been clearly defined.</p>","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"6 4","pages":"411-427"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878991/pdf/nihms-1861566.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10592870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Role of Tumor Size Reduction >50% after Neoadjuvant Chemotherapy for Breast Cancer","authors":"M. Giani, K. Tavella, Irene Renda, Enrico Tartarotti, J. Nori, E. Vanzi, S. Bianchi, T. Susini","doi":"10.26502/jcsct.5079174","DOIUrl":"https://doi.org/10.26502/jcsct.5079174","url":null,"abstract":"Purpose : We evaluated the efficacy of neoadjuvant chemotherapy in reducing locally advanced and early breast cancers size, improving breast-conserving surgery rates and its long-term outcomes. Our first aim was to test whether patients achieving a partial pathological response of good quality after neoadjuvant chemotherapy (tumor shrinkage >50% from the original clinical-instrumental size to the size evaluated by the pathologist on the surgical specimen) had better disease-free and overall survival rates than those with a tumor size reduction <50%. Patients and Methods : We analyzed 64 patients initially candidate to mastectomy, treated with neoadjuvant chemotherapy and subsequent surgery at our institution. Results : We observed tumor size reduction in 95% of the cases resulting in downstaging in 67.2% of the patients. Women with tumor size reduction >50% after NACT had better 10-years disease-free survival and overall survival rates than women with reduction <50% (p=0.002 and p<0.05, respectively). In a multivariate analysis, tumor size reduction >50% (HR=4.29, p=0.004) was an independent predictor of disease-free survival, whereas significance was not reached concerning overall survival. Treatment with neoadjuvant chemotherapy allowed to half the rate of mastectomy, as breast-conserving surgery was used in 50% of the cases. Overall, we had recurrences in 37.5% patients. We found no significant increase in local or distant recurrences after breast conserving surgery, as compared with mastectomy. Conclusions : Our data suggest that a tumor size reduction >50% after neoadjuvant chemotherapy may represent a prognostic factor for low risk of recurrence. The use of breast-conserving surgery was not associated with significantly higher risk of local relapse.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}